Abstract
The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.
Current Cancer Drug Targets
Title: HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Volume: 9 Issue: 4
Author(s): Jeremy Chien, Mara Campioni, Viji Shridhar and Alfonso Baldi
Affiliation:
Abstract: The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.
Export Options
About this article
Cite this article as:
Chien Jeremy, Campioni Mara, Shridhar Viji and Baldi Alfonso, HtrA Serine Proteases as Potential Therapeutic Targets in Cancer, Current Cancer Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/156800909788486704
DOI https://dx.doi.org/10.2174/156800909788486704 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 3
Current Drug Targets The Involvement of ERCC2/XPD and ERCC6/CSB Wild Type Alleles in Protection Against Aging and Cancer
Current Aging Science Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Ethnobotanical Survey of Medicinal Plants used to Treat Cardiovascular Disorders in Ghasemloo Valley of Urmia City
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Controlled Releases of FGF-2 and Paclitaxel from Chitosan Hydrogels and their Subsequent Effects on Wound Repair, Angiogenesis, and Tumor Growth
Current Drug Delivery Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Proteomic Classification of Breast Cancer
Current Drug Targets Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Computed Tomographic Evaluation of Colonic Diverticulum Complications
Current Medical Imaging The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology